levobupivacaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| local anaesthetics | 4 | 27262-47-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
S-enantiomer of bupivacaine, local anaesthetic
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.17 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 13.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.49 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.03 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 0.79 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 5, 1999 | FDA | PURDUE PHARMA LP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mental status changes postoperative | 67.54 | 49.62 | 9 | 500 | 174 | 50604441 |
| Confusion postoperative | 66.60 | 49.62 | 9 | 500 | 194 | 50604421 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic reaction | 92.15 | 45.23 | 32 | 618 | 68632 | 64429450 |
| Mental status changes postoperative | 59.83 | 45.23 | 8 | 642 | 158 | 64497924 |
| Confusion postoperative | 58.11 | 45.23 | 8 | 642 | 198 | 64497884 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N01BB10 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Amides |
| MeSH PA | D000777 | Anesthetics |
| MeSH PA | D000779 | Anesthetics, Local |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D018689 | Sensory System Agents |
| CHEBI has role | CHEBI:36333 | local anesthetics |
| CHEBI has role | CHEBI:37733 | EC 3.1.1.8 inhibitor |
| CHEBI has role | CHEBI:37887 | adrenergic blockers |
| CHEBI has role | CHEBI:59941 | amphiphiles |
| CHEBI has role | CHEBI:60186 | SERCA inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anesthesia for cesarean section | indication | 4847005 | |
| Local anesthesia | indication | 386761002 | |
| Regional Anesthesia for Surgery | indication | ||
| Regional Anesthesia for Labor Pain | indication | ||
| Major Nerve Block for Surgery | indication | ||
| Regional Anesthesia for Postoperative Pain | indication | ||
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Deficiency of cholinesterase | contraindication | 360607009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.24 | acidic |
| pKa2 | 7.92 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 4 subunit alpha | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL | |||||
| Sodium channel protein type 1 subunit alpha | Ion channel | IC50 | 5.79 | WOMBAT-PK | |||||
| Prostaglandin E2 receptor EP1 subtype | GPCR | WOMBAT-PK | |||||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6.71 | DRUG MATRIX | |||||
| 5-hydroxytryptamine receptor 3A | Ion channel | WOMBAT-PK | |||||||
| Potassium voltage-gated channel subfamily D member 3 | Ion channel | IC50 | 4.50 | WOMBAT-PK | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.89 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily A member 5 | Ion channel | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4021287 | VUID |
| N0000148724 | NUI |
| D01287 | KEGG_DRUG |
| 27262-48-2 | SECONDARY_CAS_RN |
| 259453 | RXNORM |
| C0873118 | UMLSCUI |
| CHEBI:6149 | CHEBI |
| CHEMBL1201193 | ChEMBL_ID |
| DB01002 | DRUGBANK_ID |
| D000077554 | MESH_DESCRIPTOR_UI |
| 92253 | PUBCHEM_CID |
| 7211 | IUPHAR_LIGAND_ID |
| 7465 | INN_ID |
| A5H73K9U3W | UNII |
| 8289 | MMSL |
| d04449 | MMSL |
| 008081 | NDDF |
| 008082 | NDDF |
| 4021287 | VANDF |
| 4021288 | VANDF |
| CHEMBL1200749 | ChEMBL_ID |
| 116103003 | SNOMEDCT_US |
| 387011006 | SNOMEDCT_US |
| 412237003 | SNOMEDCT_US |
Pharmaceutical products:
None